BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 33446563)

  • 1. The Oxford Classic Links Epithelial-to-Mesenchymal Transition to Immunosuppression in Poor Prognosis Ovarian Cancers.
    Hu Z; Cunnea P; Zhong Z; Lu H; Osagie OI; Campo L; Artibani M; Nixon K; Ploski J; Santana Gonzalez L; Alsaadi A; Wietek N; Damato S; Dhar S; Blagden SP; Yau C; Hester J; Albukhari A; Aboagye EO; Fotopoulou C; Ahmed A
    Clin Cancer Res; 2021 Mar; 27(5):1570-1579. PubMed ID: 33446563
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression and prognostic significance of epithelial-mesenchymal transition-related markers and phenotype in serous ovarian cancer.
    Song IH; Kim KR; Lim S; Kim SH; Sung CO
    Pathol Res Pract; 2018 Oct; 214(10):1564-1571. PubMed ID: 30082157
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment Outcomes of Epithelial Ovarian Cancers Following Maximum Cytoreduction and Adjuvant Paclitaxel-Carboplatin Chemotherapy: Egyptian NCI Experience.
    Nassar HR; Zeeneldin AA; Helal AM; Ismail YM; Elsayed AM; Elbassuiony MA; Moneer MM
    Asian Pac J Cancer Prev; 2015; 16(16):7237-42. PubMed ID: 26514517
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ascites regression following neoadjuvant chemotherapy in prediction of treatment outcome among stage IIIc to IV high-grade serous ovarian cancer.
    Xu X; Deng F; Lv M; Ren B; Guo W; Chen X
    J Ovarian Res; 2016 Dec; 9(1):85. PubMed ID: 27912779
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIPEC plus EPIC paclitaxel for maximal perioperative treatments of advanced epithelial ovarian cancer. Long-term results of a pilot study.
    Sugarbaker PH; Stuart OA
    Surg Oncol; 2020 Dec; 35():441-446. PubMed ID: 33039850
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low grade serous ovarian carcinoma: identifying variations in practice patterns.
    Siemon J; Gershenson DM; Slomovitz B; Schlumbrecht M
    Int J Gynecol Cancer; 2019 Jan; 29(1):174-180. PubMed ID: 30640701
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical characteristics and prognosis of epithelial ovarian cancer in young women].
    Tang L; Zheng M; Xiong Y; Ding H; Liu FY
    Ai Zheng; 2008 Sep; 27(9):951-5. PubMed ID: 18799034
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Machine learning-assisted analysis of epithelial mesenchymal transition pathway for prognostic stratification and immune infiltration assessment in ovarian cancer.
    Li Q; Xiao X; Feng J; Yan R; Xi J
    Front Endocrinol (Lausanne); 2023; 14():1196094. PubMed ID: 37404304
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hyperthermic Intraperitoneal Chemotherapy after Secondary Cytoreduction in Epithelial Ovarian Cancer: A Single-center Comparative Analysis.
    Baiocchi G; Ferreira FO; Mantoan H; da Costa AA; Faloppa CC; Kumagai LY; de Mello CA; Takahashi RM; Nakagawa WT; Aguiar S; Lopes A
    Ann Surg Oncol; 2016 Apr; 23(4):1294-301. PubMed ID: 26628430
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemotherapy Response Score: Development and Validation of a System to Quantify Histopathologic Response to Neoadjuvant Chemotherapy in Tubo-Ovarian High-Grade Serous Carcinoma.
    Böhm S; Faruqi A; Said I; Lockley M; Brockbank E; Jeyarajah A; Fitzpatrick A; Ennis D; Dowe T; Santos JL; Cook LS; Tinker AV; Le ND; Gilks CB; Singh N
    J Clin Oncol; 2015 Aug; 33(22):2457-63. PubMed ID: 26124480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Upfront debulking surgery versus interval debulking surgery for advanced tubo-ovarian high-grade serous carcinoma and diffuse peritoneal metastases treated with peritonectomy procedures plus HIPEC.
    Biacchi D; Accarpio F; Ansaloni L; Macrì A; Ciardi A; Federici O; Spagnoli A; Cavaliere D; Vaira M; Sapienza P; Sammartino P
    J Surg Oncol; 2019 Dec; 120(7):1208-1219. PubMed ID: 31531879
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low RAP80 mRNA expression correlates with shorter survival in sporadic high-grade serous ovarian carcinoma.
    Romeo M; Karachaliou N; Chaid I; Queralt C; De Aguirre I; Del Carmen Gómez M; Sanchez-Ronco M; Radua J; Ramírez JL; Rosell R
    Int J Biol Markers; 2017 Mar; 32(1):e90-e95. PubMed ID: 27443420
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of neoadjuvant chemotherapy cycles prior to interval surgery in patients with advanced epithelial ovarian cancer.
    Colombo PE; Labaki M; Fabbro M; Bertrand M; Mourregot A; Gutowski M; Saint-Aubert B; Quenet F; Rouanet P; Mollevi C
    Gynecol Oncol; 2014 Nov; 135(2):223-30. PubMed ID: 25220627
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HOXA4/HOXB3 gene expression signature as a biomarker of recurrence in patients with high-grade serous ovarian cancer following primary cytoreductive surgery and first-line adjuvant chemotherapy.
    Miller KR; Patel JN; Zhang Q; Norris EJ; Symanowski J; Michener C; Sehouli J; Braicu I; Destephanis DD; Sutker AP; Jones W; Livasy CA; Biscotti C; Ganapathi RN; Tait DL; Ganapathi MK
    Gynecol Oncol; 2018 Apr; 149(1):155-162. PubMed ID: 29402501
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostaglandin D2 expression is prognostic in high‑grade serous ovarian cancer.
    Alves MR; Do Amaral NS; Marchi FA; Silva FIB; Da Costa AABA; Carvalho KC; Baiocchi G; Soares FA; De Brot L; Rocha RM
    Oncol Rep; 2019 Apr; 41(4):2254-2264. PubMed ID: 30720106
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Treatment and prognostic analysis of ovarian cancer patients with isolated region of lymph node recurrence].
    Tu H; Huang H; Huang QD; Li Z; Feng YL; Liu JH
    Zhonghua Fu Chan Ke Za Zhi; 2012 Dec; 47(12):928-33. PubMed ID: 23324194
    [TBL] [Abstract][Full Text] [Related]  

  • 17. miR-181a overexpression predicts the poor treatment response and early-progression of serous ovarian cancer patients.
    Panoutsopoulou K; Avgeris M; Magkou P; Mavridis K; Dreyer T; Dorn J; Obermayr E; Reinthaller A; Michaelidou K; Mahner S; Vergote I; Loverix L; Braicu I; Sehouli J; Zeillinger R; Magdolen V; Scorilas A
    Int J Cancer; 2020 Dec; 147(12):3560-3573. PubMed ID: 32621752
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low junctional adhesion molecule-A expression is associated with an epithelial to mesenchymal transition and poorer outcomes in high-grade serous carcinoma of uterine adnexa.
    Communal L; Medrano M; Sircoulomb F; Paterson J; Köbel M; Rahimi K; Hoskins P; Tu D; Lheureux S; Oza A; Ailles L; Provencher D; Rottapel R; Mes-Masson AM
    Mod Pathol; 2020 Nov; 33(11):2361-2377. PubMed ID: 32514162
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment decision-making in elderly women with ovarian cancer: an age-based comparison.
    van Walree IC; van Soolingen NJ; Hamaker ME; Smorenburg CH; Louwers JA; van Huis-Tanja LH
    Int J Gynecol Cancer; 2019 Jan; 29(1):158-165. PubMed ID: 30640699
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma].
    Mao YN; Zeng LX; Li YH; Liu YZ; Wu JY; Li L; Wang Q
    Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):687-696. PubMed ID: 29060967
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.